CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 123 enrolled
Drug / intervention
levonorgestrel and ethinyl estradioldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01250210
NCT01250210Phase 2Completed

Evaluation of Pharmacodynamic Effects on Ovulation Suppression and Cycle Control of Three Agile Contraceptive Patches Containing Different Doses of Ethinyl Estradiol(EE)During Three Cycles of Administration

Agile Therapeutics·interventional·Posted Nov 30, 2010·Updated Jul 5, 2018

In Brief

A Phase 2 clinical trial evaluating levonorgestrel and ethinyl estradiol for Ovulation Suppression. Completed, enrolled 123 participants across 11 sites.

Detailed Summary

Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 30, 2010
Enrollment StartSep 1, 2007
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.6 years ago

Interventions

levonorgestrel and ethinyl estradioldrug

pregnancy prevention